Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Oct 24;369(17):1620-8.
doi: 10.1056/NEJMoa1213096.

HLA-B*13:01 and the dapsone hypersensitivity syndrome

F-R Zhang  1 , H Liu, A Irwanto, X-A Fu, Y Li, G-Q Yu, Y-X Yu, M-F Chen, H-Q Low, J-H Li, F-F Bao, J-N Foo, J-X Bei, X-M Jia, J Liu, H Liany, N Wang, G-Y Niu, Z-Z Wang, B-Q Shi, H-Q Tian, H-X Liu, S-S Ma, Y Zhou, J-B You, Q Yang, C Wang, T-S Chu, D-C Liu, X-L Yu, Y-H Sun, Y Ning, Z-H Wei, S-L Chen, X-C Chen, Z-X Zhang, Y-X Liu, S L Pulit, W-B Wu, Z-Y Zheng, R-D Yang, H Long, Z-S Liu, J-Q Wang, M Li, L-H Zhang, H Wang, L-M Wang, P Xiao, J-L Li, Z-M Huang, J-X Huang, Z Li, J Liu, L Xiong, J Yang, X-D Wang, D-B Yu, X-M Lu, G-Z Zhou, L-B Yan, J-P Shen, G-C Zhang, Y-X Zeng, P I W de Bakker, S-M Chen, J-J Liu
Affiliations
Free article

HLA-B*13:01 and the dapsone hypersensitivity syndrome

F-R Zhang et al. N Engl J Med. .
Free article

Abstract

Background: Dapsone is used in the treatment of infections and inflammatory diseases. The dapsone hypersensitivity syndrome, which is associated with a reported mortality of 9.9%, develops in about 0.5 to 3.6% of persons treated with the drug. Currently, no tests are available to predict the risk of the dapsone hypersensitivity syndrome.

Methods: We performed a genomewide association study involving 872 participants who had received dapsone as part of multidrug therapy for leprosy (39 participants with the dapsone hypersensitivity syndrome and 833 controls), using log-additive tests of single-nucleotide polymorphisms (SNPs) and imputed HLA molecules. For a replication analysis, we genotyped 24 SNPs in an additional 31 participants with the dapsone hypersensitivity syndrome and 1089 controls and performed next-generation sequencing for HLA-B and HLA-C typing at four-digit resolution in an independent series of 37 participants with the dapsone hypersensitivity syndrome and 201 controls.

Results: Genomewide association analysis showed that SNP rs2844573, located between the HLA-B and MICA loci, was significantly associated with the dapsone hypersensitivity syndrome among patients with leprosy (odds ratio, 6.18; P=3.84×10(-13)). HLA-B*13:01 was confirmed to be a risk factor for the dapsone hypersensitivity syndrome (odds ratio, 20.53; P=6.84×10(-25)). The presence of HLA-B*13:01 had a sensitivity of 85.5% and a specificity of 85.7% as a predictor of the dapsone hypersensitivity syndrome, and its absence was associated with a reduction in risk by a factor of 7 (from 1.4% to 0.2%). HLA-B*13:01 is present in about 2 to 20% of Chinese persons, 1.5% of Japanese persons, 1 to 12% of Indians, and 2 to 4% of Southeast Asians but is largely absent in Europeans and Africans.

Conclusions: HLA-B*13:01 was associated with the development of the dapsone hypersensitivity syndrome among patients with leprosy. (Funded by the National Natural Science Foundation of China and others.).

PubMed Disclaimer

Comment in

  • Different roads, same destination.
    Wang B. Wang B. J Invest Dermatol. 2014 Apr;134(4):1154-1155. doi: 10.1038/jid.2014.9. Epub 2014 Jan 3. J Invest Dermatol. 2014. PMID: 24390133 No abstract available.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

Publication types